Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p24
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 24/191)
Character Range: 9720953–9733547

P4996          CN4996           Captopril                                                                                                                                                                  Patients unable to take a solid dose form of an ACE inhibitor.

C4997               P4997          CN4997           Progesterone                                                                                                                                                               Assisted Reproductive Technology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 4997
                                                                                                                                                                                                                               The treatment must be for luteal phase support as part of an assisted reproductive technology (ART) treatment cycle for infertile women; AND
                                                                                                                                                                                                                               Patient must be receiving medical services as described in items 13200 or 13201 of the Medicare Benefits Schedule.
                                                                                                                                                                                                                               The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement.
C4998               P4998          CN4998           Clozapine                                                                                                                                                                  Schizophrenia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 4998
                                                                                                                                                                                                                               Continuing treatment
                                                                                                                                                                                                                               Must be treated by a psychiatrist; or
                                                                                                                                                                                                                               Must be treated by an authorised medical practitioner, with the agreement of the treating psychiatrist; AND
                                                                                                                                                                                                                               Patient must have previously received PBS-subsidised therapy with this drug for this condition; AND
                                                                                                                                                                                                                               Patient must have completed at least 18 weeks therapy; AND
                                                                                                                                                                                                                               Patient must be on a clozapine dosage considered stable by a treating psychiatrist; AND
                                                                                                                                                                                                                               The treatment must be under the supervision and direction of a psychiatrist reviewing the patient at regular intervals.
                                                                                                                                                                                                                               A medical practitioner should request a quantity sufficient for up to one month's supply. Up to 5 repeats will be authorised.
C5000               P5000          CN5000           Ganciclovir                                                                                                                                                                Cytomegalovirus retinitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 5000
                                                                                                                                                                                                                               Patient must be severely immunocompromised, including due to HIV infection.
C5004               P5004          CN5004           Peginterferon alfa-2a                                                                                                                                                      Chronic hepatitis C infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 5004
                                                                                                                                                                                                                               Must be treated in an accredited treatment centre;
                                                                                                                                                                                                                               Patient must be aged 18 years or older;
                                                                                                                                                                                                                               Patient must not be pregnant or breastfeeding, and must be using an effective form of contraception if female and of child-bearing age;
                                                                                                                                                                                                                               Patient must have compensated liver disease; AND
                                                                                                                                                                                                                               Patient must not have received prior interferon alfa or peginterferon alfa treatment for hepatitis C; AND
                                                                                                                                                                                                                               Patient must have a contraindication to ribavirin; AND
                                                                                                                                                                                                                               The treatment must cease unless the results of an HCV RNA quantitative assay at week 12 (performed at the same laboratory using the same test) show that plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop; AND
                                                                                                                                                                                                                               The treatment must be limited to a maximum duration of 48 weeks.
                                                                                                                                                                                                                               Evidence of chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive) must be documented in the patient's medical records.
C5008               P5008          CN5008           Maraviroc                                                                                                                                                                  HIV infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 5008
                                                                                                                                                                                                                               Patient must be infected with CCR5-tropic HIV-1; AND
                                                                                                                                                                                                                               The treatment must be in addition to optimised background therapy; AND
                                                                                                                                                                                                                               The treatment must be in combination with other antiretroviral agents; AND
                                                                                                                                                                                                                               Patient must